In this study, we monitored patients with advanced malignant tumors who received anti-PD-1 therapy to observe the characteristic of anti-PD-1 therapy-induced thyroid dysfunction and its correlation with prognosis.

Inclusion Criteria:

• Eighteen years or older
• Confirmed diagnosis of malignancy
• Received anti-PD-1 therapy

Exclusion Criteria:

• Thyroid malignancy or history of thyroid malignancy
• Thyroid dysfunction before anti-PD-1 therapies
• Previous ICIs treatment
• Less than 2 cycles of anti-PD-1 treatment
• No thyroid function monitoring during treatment
• Known pituitary disease
• Pregnancy.

Patients with advanced carcinoma who received anti-PD-1 therapy at East Branch of Qilu Hospital of Shandong University